Andrew is ranked in Tier 1 for mid-market M&A by both Chambers UK and legal 500 directories as well as being listed as one of The Lawyer's Hot 100. Andrew's clients describe him as 'a strong negotiator and problem solver' as well as 'fast and pragmatic and able to understand our needs very well'.

He has particular expertise in the Life Sciences sector and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries. Andrew has a wealth of expertise in Indian and Russian M&A, having acted on some of the largest multi-billion dollar transactions to have taken place in those jurisdictions.

Whilst at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Aspen Healthcare sold to Canadian-based property trust

2021年9月27日

作者 Andrew McLean 以及 Andrew Edge

点击此处了解更多
酒店与休闲

Advising Apollo Therapeutics on $145 million financing

2021年6月21日

作者 Andrew Edge 以及 Chris Cowley

点击此处了解更多
公司/并购与资本市场

Taylor Wessing advises Databricks on acquisition of 8080 Labs

2021年10月21日

作者

点击此处了解更多
公司/并购与资本市场

Advising Current Health on Best Buy acquisition

2021年10月21日

作者 Howard Palmer

点击此处了解更多

与我会面: